To investigate the expression pattern of microRNA-451 (miR-451) in patients with colorectal carcinoma and correlate with the expression of its target gene MIF (macrophage migration inhibitory factor). Methods Matched cancer and non-cancer fresh frozen tissues were prospectively collected from 70 patients (35 men and 35 women) who underwent resection of colorectal adenocarcinoma. These tissues collected were extracted for miR and complementary DNA conversion. Then, miR-451 expressions in these tissues were measured by quantitative real-time PCR. The expression was correlated with clinical and pathological parameters of these patients. In addition, paraffin blocks of 10 colorectal carcinomas with lowest expression of miR-451 were used for the study of MIF protein expression by immunohistochemistry. Results miR-451 was downregulated in majority of the colorectal cancer tissues when compared with their matched normal tissues (84.3%, n=59/70). Downregulation of miR-451 correlates significantly with presence of coexisting adenoma (91.4%, p=0.025). In addition, persistence of cancer or cancer recurrence after surgery showed significant correlation with downregulation of miR-451 (80% vs 0%; p=0.028). There is no significant correlation between miR-451 expression and age, gender of the patients as well as size, grades, pathological stages, presence of lymphovascular permeation, perineural invasion and microsatellite instability status of the colorectal carcinoma ( p>0.05). Majority of the cases (80%) with low expression of miR-451 showed high levels of MIF protein expression confirming the inverse relationship between miR-451 and MIF expressions. Conclusions The results showed that miR-451 could play a role in development and progression of colorectal cancer and likely by targeting MIF.
INTRODUCTION
MicroRNAs (miRs) are important in the pathogenesis and have potential applications in colorectal carcinoma. [1] [2] [3] [4] [5] Among these, miR-126, miR-1288 and miR-498 have been shown in our previous studies to be important in the pathogenesis of colorectal carcinoma by analysing large cohort of clinical samples of the cancer. [2] [3] [4] In addition, studies have shown that other miRs, in particular miR-21, miR-200 and miR-215, are commonly involved in regulation of cancer stem cells in colorectal carcinoma.
Among the miRs, miR-451 has important roles in pathogenesis of colorectal cancer and with downstream target identified. miR-451 is located on chromosome 17 at 17q11.2 of human genome. 6 High expression level of miR-451 was reported in human foetuses when compared with adults, indicating that miR-451 could play an important role in cell growth and differentiation. 7 8 miR-451 acts as a tumour suppresser gene in modulating different molecular pathways in many cancers. [9] [10] [11] [12] [13] [14] To exert its effects, miR-451 targets several genes and the most significant target is MIF (macrophage migration inhibitory factor). 15 16 MIF protein is a proinflammatory cytokine that has association with pathogenesis of chronic inflammatory diseases, 17 and many types of cancers. 18 19 Recent studies have proven that MIF has the potential to act as a target against cancer as its expression in human cancers correlates positively with the tumour aggressiveness and metastatic potential. [20] [21] [22] Till now, tumour suppressive properties of miR-451in colorectal carcinoma have been studied mostly on in vitro analysis. Moreover, previous studies did not correlate the coexpression pattern of miR-451 and its target MIF in cancer tissues. Thus, this study aims to analyse the role of miR-451 in colorectal carcinoma by identification of its expression pattern in conjunction with MIF protein expression status and correlate this expression with different clinicopathological parameters of the patients with colorectal carcinoma.
MATERIALS AND METHODS

Recruitment of the tissues and sample selection
A total of 70 fresh frozen colorectal cancer tissue specimens with matched non-cancer tissues were prospectively recruited and stored at −80°C. The samples were collected from patients with colorectal carcinoma who have undergone resection. A signed consent from each of the participating patients was also obtained. Formalin-fixed paraffin tissue blocks from the same tissues were also obtained for MIF protein expression analysis. The fresh frozen colorectal tissues were sectioned using a cryostat (Leica Biosystems, Wetzlar, Hesse, Germany) and histological analysis was made after staining with H&E staining. 
Clinical and pathological data of the patients
The surgical specimens of colorectal cancer were processed for pathological examination. All the histological sections of the colorectal cancer were examined by the author (AK-YL).
There are 70 patients (35 men and 35 women) with colorectal adenocarcinoma collected. The mean age of the patients was 70 years (range from 24 to 91 years). The size of the cancer was classified into two groups-less than 40 mm (n=39) and more or equal to 40 mm (n=31). Fifty-four carcinomas were located in colon and 16 were in the rectum. The cancer was graded according to the WHO. 23 Staging of the cancer was done according to TNM (tumour, lymph node, metastasis) classification. 24 The other pathological parameters including the association of the colorectal adenoma, presence of lymphovascular permeation, perineural invasion and hereditary non-polyposis colorectal cancer (HNPCC) were also noted. Microsatellite instability (MSI) was tested in these cases by immunohistochemistry on four proteins (MLH1, PMS2, MSH2 and MSH6) as described previously. 2 All the patients were followed up clinically according to standard protocol. The management of the patients was determined in the multidisciplinary team meeting. Radiological examination, endoscopic examination and haematological examination were offered to the patients by standard protocol and according to the clinical status of the patient. The patients were reviewed regularly by the surgical and/or oncology teams. Persistence ( presence of residual tumour or metastases) or recurrence of the cancer after surgery was recorded. If patients have no persistent disease or cancer recurrence after 5 years, they were then referred to be followed up by their general practitioners.
miR extraction and complementary DNA conversion
Total RNA including miR was extracted from the fresh frozen human tissues after cryotomy. In brief, tissues were sectioned in thin slices (5 mm) and followed by extraction using Qiagen miRNeasy Mini Kit, which is specific for purification the total RNA including miR from fresh frozen tissues (Qiagen, Hilden, North Rhine-Westphalia, Germany). RNA quality was assessed by using a Nano Drop ND.1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, Massachusetts, USA). Purity of RNA was obtained by checking the optical density 260/280 ratio and the concentration of RNA was noted in ng/mL.
Reverse transcription reactions were performed using 1 μg total RNA in a final reaction volume of 20 mL. RNA was converted to complementary DNA (cDNA) using miScript Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. Each cDNA sample was diluted to 1.5 ng/mL in order to provide uniformly concentrated sample for miR quantitative real-time PCR. The sample was stored at −20°C till the PCR analysis.
Quantitative Real-time PCR
An IQ5 Multicolour Real-Time PCR Detection system (Bio-Rad, Hercules, California, USA) was used to analyse the miR-451 expression changes. PCR was performed in a total volume of 20 mL reaction mixture containing 10 mL 2× QuantiTect SYBR Green PCR Master Mix, 2 mL 10× miScript Universal Primer, 2 mL 10× miScript Primer Assay (Hs_miR-451_1) (Qiagen) and 4 mL of cDNA template at 1.5 ng/mL concentration. RNU6B RNA (Hs_RNU6B_2 miScript Primer Assay, Qiagen) was used for normalising the amount of target miR. The primer sequences used for miR-451a and RNU6B were 5 0 AAACCGUU ACCAUUACUGAGUU and 5 0 TGACACGCAAATTCGTGAAG respectively (Qiagen). All the samples (cancer and non-cancer)
were run in triplicates. The fold change in the target gene for the results of quantitative amplification was calculated for each sample using 2 −ΔΔCT (fold change) method as previously reported.
2-4 A fold change more than 2 was considered as high miR-451 expression and a fold change of less than 1 was regarded as low expression for miR-451.
Immunohistochemistry of MIF in colorectal cancer tissues
Tissues from 10 patients with colorectal adenocarcinoma with lowest expression of miR-451 noted in the previous experiment were used for MIF protein expression analysis. A high PH ENVision FLEX Mini Kit (Dako, Glostrup, Hovedstaden, Denmark) was used for the immunohistochemical analysis of MIF protein. In brief, deparaffinised and rehydrated sections (4 μm) were first processed for antigen retrieval in citrate buffer (at pH 6.0) for 15 min in a microwave oven and then blocked with peroxidase blocking reagent for 8 min. Tissues were incubated with a rabbit antihuman MIF polyclonal antibody (FL-115, 1:150 dilution; Santa Cruz Biotechnology, Santa Cruz, California, USA) for 60 min at room temperature. The slides were then incubated with a horseradish peroxidase-conjugated rabbit secondary antibody (Dako) for 25 min at room temperature. Visualisation of staining was done by using 3, 3 0 -diaminobenzidine (Dako) to produce a brown colour, and then counterstained with haematoxylin. A colon adenocarcinoma tissue that showed strong nuclear staining was used as a positive control in each run of the experiment. Negative control sample was prepared with the same procedure, except that tissue was not incubated with the primary antibody.
The staining was counted by a pathologist (AK-YL) under a standard light microscope. A grading scale ranging from 0 to 3 was used for this assessment, where 0 represented a negative staining, 1 represented weak staining (1% to 30%), 2 represented moderate staining (31% to 70%) and 3 represented strong staining (>70%). Assessment of the slides according to the extent of positive MIF staining was also taken in consideration.
Statistical analysis
Statistical analysis was done by using the Statistical Package for Social Sciences (IBM SPSS, V.23, New York, New York, USA). χ 2 test or likelihood ratio was used for categorical variables. Pearson correlation test was used for continuous variables. Independent t-test was performed for the analysis of continuous variables, and a value <0.05 for these tests was considered as significant.
RESULTS
miR-451 expression pattern and correlation to clinicopathological parameters of the patients
MiR-451 expression was downregulated in colorectal carcinoma tissues when compared with matched non-cancer tissues (table 1, figure 1 ). Approximately 84.3% (59/70) of the colorectal carcinomas showed reduced expression levels of miR-451 and upregulation/overexpression was noted in only 7.1% (5/70) of patients. The remaining patients (n=4) did not show any change in expression levels for miR-451. The mean expression fold change for miR-451 after normalising with matched non-tumour tissues was 0.46 (ranging from 0.01 to 2.78) with SD of 0.61 (ie, 0.46 ±0.61).
Downregulation of miR-451 was noted to be predominant in colorectal carcinoma with coexisting adenoma(s) when compared with cancers without coexisting colorectal adenoma(s) (91.4%, 32/35 vs 77.1%, 27/35, p=0.02). All the cases with high expression of miR-451 did not have coexisting adenoma(s) (0%, 0/5).
On clinical follow-up, cancer recurrence or persistence of cancer after surgery was detected in 29% (20/70) of the patients. All these cancers occurred within 40 months after surgery. Distant metastases (most often in either liver or omentum) were present in all these cases.
In patients with cancer recurrence or persistent disease after surgery (n=20), approximately 80% of the patients had reduced levels of miR-451 expression. Recurrence of cancer was not reported in any case with high miR-451 expression ( p=0.028). There is no significant correlation between miR-451 expression and age, gender, presence of HNPCC of the patients as well as size, grades, pathological stages, presence of lymphovascular permeation, perineural invasion and MSI status of the colorectal carcinoma ( p>0.05).
Correlation between miR-451 downregulation and MIF protein expression
MIF protein was noted predominately in the nuclei of the colorectal carcinoma (table 2, figure 2 ). In the 10 cases with lowest expression of miR-451, eight cases (80%, 8/10) expressed high level of MIF protein (score=2 or 3). Among these eight cases, MIF protein showed nuclear staining in five cases (62.5%) and the other three (37.5%) cases showed both nuclear and cytoplasmic localisation.
DISCUSSION
In colorectal cancer, downregulation of miR-451 has been reported previously. 9 15 25 In the current study, we used wider sample size to confirm that miR-451 was downregulated in colorectal cancer tissues. Our findings support the role of miR-451 as a tumour suppressor gene in colorectal cancer and further point its possible role in cancer development. It is understood that progression from adenoma to carcinoma is an important step in development of colorectal cancer. Yin and colleagues have reported some downregulation of miR-451 in a small population of patients with colorectal adenoma and more in colorectal adenocarcinoma. 26 Our study found that there is a significant downregulation of miR-451 expression in colorectal carcinoma with coexisting adenoma. These findings may imply that miR-451 downregulation is involved in the development of colorectal adenoma, which is in the early steps of pathogenesis of colorectal carcinoma.
The current study demonstrated a significant relationship between miR-451 downregulation and recurrence of colorectal cancer after surgery. By studying circulating miRs in blood samples of 30 patients diagnosed with early-stage colon cancer, Shivapurkar and colleagues identified miR-451 among the six panel miRs (miR-15a, miR-103, miR-148a, miR-320a, miR-451, miR-596), which can be used to predict the recurrence of early-stage colon cancer. 27 Also, significant correlation of miR-451 downregulation to recurrence of tumour had been identified in gastric cancer. 15 In addition, the patients with low miR-451 showed worse overall survival rates than patients with high expression of miR-451 in gastric cancer. 28 In contrast, Brenner et al 29 stated that miR-451 overexpression has strong relationship with cancer recurrence and worse survival in gastric cancer patients. The discrepancy in these results may attribute to the difference in study population and the percentage of the tumour in the selected samples.
Our results showed no significant relationship between the expression pattern of miR-451 and clinicopathological parameters like age, gender of the patients as well as pathological stage, grade, size, lymphovascular permeation, perineural invasion and MSI status of the tumour. These findings were in concurrence with those of Liu and colleagues who studied the expression pattern of miR-451 in nasopharyngeal carcinoma and found no relationship between expression of miR-451 with age, gender of the patients as well as pathological stage, grade and size of the cancer. 13 MIF has been implicated in carcinogenesis of different types of cancers by inactivating the p53 signalling, 30 or promoting angiogenesis. 31 32 In relation to colorectal cancer, MIF was involved in development, maintenance and metastasis. [33] [34] [35] MIF was proven to have direct regulatory roles on several genes in colorectal cancer including cyclooxygenase 2, 16 vascular endothelial growth factor and matrix metallopeptidase 9. 33 Recently, MIF was reported to have important role in promoting epithelial mesenchymal transition in colorectal cancer. 34 Previous studies have identified MIF gene as a direct target for miR-451. 15 16 The current study has analysed the expression pattern of MIF protein in conjunction with the expression patterns of miR-451 to correlate and confirm their target association in human cancer tissues. Our results for the first time identified the target association of MIF with miR-451 using immunohistochemical analysis. These results are in concurrence with the findings of Bandres and colleagues who found that there is a significant inverse relationship between miR-451 expression and MIF gene in patients with gastric cancer. 15 Thus, it can be hypothesised that miR-451 plays a key role in the pathogenesis of colorectal cancer by regulating the expression level of MIF.
In this study, immunohistochemical study showed nuclear localisation of MIF in most of the cases. However, our sample size is small. Previous data mostly reported cytoplasmic expression of MIF protein. 33 36 37 Furthermore, both cytoplasmic and nuclear expression had been reported in some studies with predominance of cytoplasmic expression. Although the cytoplasmic expression of MIF protein had been reported in all the cases of lung adenocarcinoma, MIF expression was also noted in 79.7% of these cases in the nucleus. 38 Intracellular localisation of the MIF may play a role in tumour progression. Kamimura et al 38 found that the patients with lung adenocarcinoma who showed only MIF cytoplasmic localisation had shorter survival times than those with positive MIF expression in the nuclei.
In this study, the downstream effect of mR-451 on MIF protein expression is demonstrated in colorectal cancer. Larger samples of colorectal cancer are needed to document the downstream effect of MIF in the pathogenesis of colorectal cancer. It is worth noting that MIF is not the only target for miR-451. c-myc, P13K/AKT pathway, RAB14 and CAB39 have been proposed to be the downstream targets of the miR having roles in pathogenesis of cancer. Also, MDR1, Cox-2 and 14-3-3 ζ have been involved as downstream targets for miR-451 in the drug resistance in cancer cells. 39 In summary, this study for the first time correlated the expression pattern of miR-451 to several clinical and pathological features of colorectal carcinoma. The results demonstrated that miR-451 could play a role in early steps of carcinogenesis. Also, detection of miR-451 could potentially assist in prediction of cancer recurrence. Further research with increased numbers of the patients is necessary to confirm these findings.
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